31
4
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13173 |
TMPA
|
Others; AMPK | Chromatin/Epigenetic; Others; PI3K/Akt/mTOR signaling |
TMPA 是一种核受体 Nur77 和 LKB1 相互作用的拮抗剂。 | |||
T72282 |
Ebaresdax hydrochloride
|
Endogenous Metabolite | Metabolism |
Ebaresdax hydrochloride 具有镇痛活性,,可用于研究由I型或II型糖尿病引起的糖尿病性神经病变疼痛。 | |||
T24905 |
TT01001
TT-01001,TT 01001,Ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate |
Mitochondrial Metabolism | Metabolism |
TT01001 (Ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate) 是 mitoNEET 的选择性激动剂,通过改善线粒体功能障碍来减少氧化应激损伤和神经元凋亡。 TT01001可用于治疗 II 型糖尿病的研究。 | |||
T72617 |
Nampt activator-2
|
P450; NAMPT | Metabolism |
Nampt activator-2 是一种 NAMPT 激活剂(EC50 : 0.023 μM)。 Nampt activator-2 对 CYP2C9、2D6、2C19 具有亲和力,亲和力数值分别为 0.060 μM、 0.41 μM 和 0.59 μM 。Nampt activator-2 可用来研究动脉粥样硬化,肥胖,II型糖尿病,胰岛素抵抗和I型糖尿病。 | |||
T14176 |
Aleglitazar
RO0728804,R1439 |
PPAR | DNA Damage/DNA Repair; Metabolism |
Aleglitazar (R1439) 是一种高效的 PPARα/γ 双重激动剂,对人 PPARα 和 PPARγ 作用的 IC50 分别为 38 nM 和 19 nM。Aleglitazar 可用于 II 型糖尿病的研究。 | |||
T61483 |
GLP-1R modulator C5
|
Glucagon Receptor | GPCR/G Protein |
GLP-1R modulator C5 是一种小分子 GLP-1R 正变构调节剂,通过跨膜位点增强GLP-1与GLP-1R的结合,可用于研究 II 型糖尿病。。 | |||
T78169 |
Enpp-1-IN-16
|
PDE | Metabolism |
Enpp-1-IN-16 是一种靶向 ENPP1 的抑制剂,具有潜在的抗癌症活性。Enpp-1-IN-16 可用于研究胰岛素抵抗与II型糖尿病和软骨钙化病和骨关节炎类由 ENPP1介导的各类疾病。 | |||
T7656 |
Apelin-13
|
||
Apelin-13 是存在于中枢和外周神经系统由13个氨基酸组成的多肽序列,是 G 蛋白偶联受体angiotensin II protein J (APJ) 的内源性配体,对 APJ 的 EC50 值为 0.37 nM。Apelin-13 具有扩张血管和降压活性,可用于研究 2 型糖尿病综合征。 | |||
T38683 |
SCD1 inhibitor-3
SCD1-IN-3,SCD1 inhibitor-3,SCD1 inhibitor 17a |
Dehydrogenase | Metabolism |
SCD1 inhibitor-3 (ML-270) 是一种高效、口服的化合物,可以抑制SCD1,且安全性极高。 SCD1 inhibitor-3 显示出在代谢疾病(包括肥胖、二型糖尿病和血脂异常,以及痤疮和癌症等各种皮肤病)方面的巨大研究潜力。 | |||
T71354 | AMG-222 tosylate | ||
AMG-222 tosylate is a DPP-IV inhibitor in clinical development for type II diabetes. | |||
T27598 |
Imigliptin Dihydrochloride
Imigliptin |
||
Imigliptin Dihydrochloride, a selective dipeptidyl peptidase IV (DPP-4) inhibitor, is used potentially for the treatment of type II diabetes. | |||
T33598 |
Naveglitazar
LY 9818,LY-519818,LY519818,LY9818,LY-9818,LY 519818 |
||
Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes. | |||
T61124 |
α-Glucosidase-IN-9
|
||
α-Glucosidase-IN-9 (compound 7) is a highly potent α-glucosidase inhibitor with an IC50 of 55.6 μM, making it suitable for type II diabetes research [1]. | |||
T13497 |
3'-Hydroxy Repaglinide
|
Others | Others |
3'-Hydroxy Repaglinide is a main CYP2C8 metabolite of Repaglinide. Repaglinide is a carbamoylmethyl benzoic acid derivative and used as the treatment of type II diabetes. | |||
T63739 |
PTP1B-IN-15
|
||
PTP1B-IN-15 是有效的、选择性的蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制剂,对II 型糖尿病和肥胖症表现出研究潜力。 | |||
T64252 | Efpeglenatide | ||
Efpeglenatide 是一种胰高血糖素样肽 (GLP-1) 受体的长效激动剂。Efpeglenatide 能够改善糖尿病和肥胖小鼠模型的胰岛素敏感性,并减缓其体重减轻的作用。Efpeglenatide 已经被用于 II 型糖尿病的研究。 | |||
T62994 |
α-Glucosidase-IN-10
|
||
α-Glucosidase-IN-10 (compound 13) 是一种 α-glucosidase 的有效抑制剂 (IC50: 92.7 μM)。α-Glucosidase-IN-10 能够用于研究 II 型糖尿病。 | |||
T5351 |
PU-WS13
PU WS13 |
Estrogen/progestogen Receptor | Endocrinology/Hormones |
T38764 |
Amylin (8-37), human
|
||
Amylin (8-37), human, derived from human Amylin, possesses direct vasodilator effects in isolated mesenteric resistance arteries of rats. Human Amylin is a small pancreatic β-cell hormone that forms aggregates in the absence of insulin and is a key pathological feature of type II diabetes mellitus. | |||
T40115 |
GAD65 (206-220)
GAD65 (206-220) |
||
GAD65 (206-220) is a synthetic peptide derived from glutamic acid decarboxylase (GAD) 65, specifically corresponding to residues 180-188. It is known that GAD65 interacts with I-Ag7 MHC class II molecules and is a significant pancreatic antigen that self-reactive T cells target in type I diabetes mellitus. | |||
T26868 |
BMS-986118
BMS 986118 |
||
BMS-986118 is a full agonist of GPR40, is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial a | |||
T62576 |
Darglitazone Sodium
|
||
Darglitazone Sodium 是一种噻唑烷二酮,是一种选择性的、口服具有活力的 PPAR-γ (过氧化物酶体增殖物激活受体)激动剂。Darglitazone Sodium 可以有效控制血糖和脂质代谢,能够用于研究 II 型糖尿病。 | |||
TP1183 |
Amylin, amide, human
DAP amide, human |
||
Amylin, a 37-amino acid polypeptide that is structurally related to calcitonin, is secreted from the B cells of the pancreas. Amylin has anoretic effects in rats. Amylin may be responsible for the etiology of insulin resistance of type II diabetes mellitu | |||
T79225 |
α-Amylase/α-Glucosidase-IN-3
|
Glucosidase | Metabolism |
α-Amylase/α-Glucosidase-IN-3 (Compound 17) 是一种具有针对α-Amylase和α-Glucosidase的双重抑制活性的化合物,其IC50分别为0.70 μM和1.10 μM。该化合物可应用于II型糖尿病的研究领域。 | |||
T62019 | Sheng Gelieting | ||
Sheng Gelieting (CGT-8012) 是二肽基肽酶-IV 酶(DP-IV)抑制剂,IC50值为 87 nM。Sheng Gelieting 可用于研究二肽基肽酶-IV 酶相关的疾病,如糖尿病,特别是 II 型糖尿病。 | |||
T63202 |
AP5 sodium
|
||
AP5 sodium 是选择性的、有效的、口服具有活力的 GPR40 受体激动剂,对内源性配体 (AgoPAM) 表现出正向变构调节效果。AP5 sodium 在大鼠和人肌醇一磷酸 (IP1) 实验中作用于 GPR40 受体,他们的 EC50值分别为 0.49 nM 和 0.8 nM。AP5 sodium 表现出研究 II 型糖尿病的潜能。 | |||
T68491 |
Melogliptin
|
||
Melogliptin, also known as EMD-675992 and GRC-8200, is a potent and selective a dipeptidyl peptidase IV (DPP-IV) inhibitor potentially for treatment of type II diabetes. Melogliptin significantly reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.75 percent in patients receiving 50mg twice daily dose and 0.60 percent in patients receiving 100 mg once daily dose. | |||
T64189 |
NNMT-IN-3
|
||
NNMT-IN-3 (compound 14) 是一种有效的、选择性的烟酰胺 N-甲基转移酶 (NNMT) 抑制剂,在无细胞和基于细胞的实验中的 IC50 值分别为 1.1 nM 和 0.4 μM。NNMT-IN-3 能够用于肥胖、癌症、II 型糖尿病及骨骼肌减少症等疾病的研究。 | |||
T38764L |
Amylin (8-37), human acetate(135702-23-7 free base)
|
||
Amylin (8-37), human acetate(135702-23-7 free base) 源自人 Amylin,对大鼠离体肠系膜阻力动脉具有直接血管舒张作用。 Amylin (8-37), human acetate,是一种小型胰腺 β 细胞激素,在没有胰岛素的情况下会形成聚集体,是 II 型糖尿病的一个关键病理特征。 | |||
T79475 |
GPR119 agonist 2
|
||
GPR119 agonist2(化合物43)是一种口服活性的GPR119激动剂。在啮齿动物中表现出优良的药代动力学特性,并能有效提高小鼠和大鼠的葡萄糖耐受性。GPR119 agonist2有望用于研究II型糖尿病。 | |||
T72034 |
LI-2242
|
Others | Others |
LI-2242是一种强效肌醇六磷酸激酶(IP6K)抑制剂,对 IP6K1、IP6K2、IP6K3和 IPMK 的 IC50s 分别为31 nM、42 nM、8.7 nM 和1944 nM。LI-2242通过减少增强脂质吸收、脂质稳定和脂肪生成的基因的表达,改善了肝脏脂肪变性,增强体外脂肪细胞和肝细胞的线粒体耗氧率(OCR)和胰岛素信号传导。 LI-2242可改善饮食诱导的小鼠肥胖症、高血糖症和肝脂肪变性。LI-2242可用于研究 II 型糖尿病、肥胖症、代谢并发症、静脉血栓和精神疾病。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3S1612 |
kuwanon G
桑黄酮G,Moracenin B,桑黄酮 G,Kuwanone G |
Phosphatase; Antibacterial; Bombesin Receptor; AChR; AChE; Glucosidase | GPCR/G Protein; Metabolism; Microbiology/Virology; Neuroscience |
Kuwanon G (Moracenin B) 是一种从桑树中得到的黄酮类蛙皮素受体拮抗剂,具有杀菌作用。 | |||
T4723 |
D-Tagatose
塔格糖,D-(-)-Tagatose,D-塔格糖,d-tagatos |
Others; Endogenous Metabolite | Metabolism; Others |
D-Tagatose (D-(-)-Tagatose) 是自然界中发现的一种罕见的单糖,具有益生元特性。它是研究II 型糖尿病的潜在抗糖尿病药物,也是帮助提升结肠有益细菌、预防结肠癌和抑制胆固醇的益生元。它是蔗糖的替代品,也是口香糖、果汁和饮料等食品中的低热量甜味剂。 | |||
T60692 |
Masoprocol
|
||
Masoprocol (meso-Nordihydroguaiaretic acid) 是口服有效的脂氧合酶 (lipoxygenase) 抑制剂。Masoprocol 具有出抗高血糖活性,可用于 II 型糖尿病的研究。 Masoprocol 可降低体内肝甘油三酯和葡萄糖浓度。 | |||
T36563 |
(E)-Guggulsterone
|
||
Bile acids are essential for solubilization and transport of dietary lipids, are the major products of cholesterol catabolism, and are physiological ligands for farnesoid X receptor (FXR), a nuclear receptor that regulates genes involved in lipid metabolism.1They are also inherently cytotoxic, as physiological imbalance contributes to increased oxidative stress.2,3Bile acid-controlled signaling pathways are promising novel targets to treat such metabolic diseases as obesity, type II diabetes, hy... |